Dose: 0.114 to 0.228 mg/kg
Single Dose: 0.17 (0.171)
Frequency: 8 hourly
Route: PO
Instructions: Maintenance, As Required.

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Dose: Rarely used in this Age Group
Single Dose:
Frequency:
Route:
Instructions:

. It is of Synthetic origin and belongs to Guanidine Salt. It belongs to Antihypertensive Agents pharmacological group.The Molecular Weight of Bethanidine (Sulphate) is 226.30. Its pKa is 12.0.

Bethanidine (Sulphate) is contraindicated in conditions like Phaeochromocytoma,Renal failure.

The severe or irreversible adverse effects of Bethanidine (Sulphate), which give rise to further complications include Diarrhoea, Thrombocytopenia, Impotence.Bethanidine (Sulphate) produces potentially life-threatening effects which include Severe Hypotension, Myocardial infarction, Angina pectoris, Cerebrovascular insufficiency, Syncope, Cerebral infarction. which are responsible for the discontinuation of Bethanidine (Sulphate) therapy.The signs and symptoms that are produced after the acute overdosage of Bethanidine (Sulphate) include Bradycardia, Postural hypotension, Dizziness, Fainting.The symptomatic adverse reactions produced by Bethanidine (Sulphate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Vomiting, Nasal stiffiness.

Bethanidine (Sulphate) is primarily indicated in conditions like Hypertension.

Bethanidine (Sulphate) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAdrenalineAlcoholAmitriptyline (HCl)Chlorpromazine (HCl)Desipramine (HCl)Dothiepin (HCl)Doxepin (HCl)Imipramine (HCl)Trimipramine (Maleate) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tabs Store Between 20°C-25°C.

Bethanidine (beta-blocker) should not be given to patients with bronchospasm, asthma, with history of obstructive airway disease, metabolic acidosis, partial heart block, sinus bradycardia or psoriasis. The dose may need to reduce in patients with renal (kidney) or hepatic (liver) dysfunction. Patients with long term treatment with beta-blockers should have their medication discontinued gradually over a period of 1 to 2 weeks, because it may result in angina, myocardial infraction (MI), ventricular arrhythmia or death. This drug should be used only if clearly needed during pregnancy or lactation.